Bio-Techne Corp

Bio-Techne issued supplemental information to the proxy materials for its planned merger with Merck KGaA after a shareholder lawsuit filed on Sept. 9 and several demand letters. The suit alleges that material information was omitted or misrepresented in the proxy statement and seeks a court order blocking the shareholder vote scheduled for Sept. 23. Bio-Techne says the allegations are unfounded but has voluntarily provided extra details, including on prior takeover talks, the terms of Goldman Sachs’s engagement and updated financial metrics to enable the vote. The company also reported Q4 revenue of $321.2 million, beating expectations, with slightly lower adjusted EPS of $0.52; the merger would make Bio-Techne a wholly owned subsidiary of Merck, subject to approvals. » Mere på de.investing.com

Bio-Techne’s shares reached a 52-week high of $72.39, giving the company a market capitalization of $11.27 billion; year-to-date the gain is 23% and the stock is up 34.94% over the past year. InvestingPro rates the stock as overvalued relative to its fair value. For the fourth quarter of fiscal 2026, Bio-Techne reported adjusted EPS of $0.52 (meeting analyst consensus) and revenue of $321.2 million, beating the $314.7 million estimate; organic growth was 3%. Bio-Techne is also in the process of being acquired by Merck KGaA, Darmstadt, Germany. » Mere på de.investing.com

The board of directors of Bio-Techne has declared a quarterly dividend of $0.08 per share for the quarter ending June 30, 2026. The dividend will be paid on August 28, 2026 to shareholders of record on August 17, 2026. Management will review future cash dividends on a quarterly basis; Bio-Techne reported net revenue of more than $1.2 billion for fiscal 2026. » Mere på de.investing.com

Bio‑Techne’s stock climbed to a 52‑week high of $72.17 and is up about 23% year‑to‑date; it has risen roughly 67% from its low. Analysts say the stock is trading near its peak and is considered overvalued by InvestingPro, with a P/E of 103.76 and a dividend yield of 0.44%. At the same time, Bio‑Techne is facing a takeover by Merck KGaA at an offer price of $73 per share and has expanded its portfolio of AI‑powered designer proteins. » Mere på de.investing.com

Bio-Techne has expanded its R&D Systems portfolio with five AI-designed proteins, including FGF-4 heat-stable, FGF-7 heat-stable, FGF-8b heat-stable, IL-3 heat-stable and IL-15 hyperactive. The proteins are designed for cell culture and cell therapy workflows and aim to improve stability, activity and scalability in applications such as stem cell maintenance, organoid development and expansion of NK and T cells. Company representatives emphasize reproducible results and seamless scaling from research to production; Bio-Techne reported net sales of more than $1.2 billion in 2025. » Mere på de.investing.com